RxDoctor Payments Data

Shawn Smith, MD

Internal Medicine · Birmingham, ALNPI 1033271994

Payments from drug & device makers

$2,419in general payments, 2019–2025

Across 153 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$905
  • Abbott$492
  • Pfizer$461
  • Johnson & Johnson$123
  • AbbVie$102
  • Dexcom, Inc.$81
  • plus $256 from 11 others

What the payments were for

  • Food & beverage$2,419100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,419 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$156,947
Medicare patients
405
Services billed
5,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide300$358,324
OzempicSemaglutide247$296,304
JardianceEmpagliflozin244$272,542
EliquisApixaban151$177,139
TrulicityDulaglutide71$96,473
Trelegy ElliptaFluticasone/Umeclidin/Vilanter98$86,393
RybelsusSemaglutide49$72,538
XareltoRivaroxaban60$50,860
LinzessLinaclotide53$50,143
Breo ElliptaFluticasone/Vilanterol78$44,011
MyrbetriqMirabegron36$30,919
CreonLipase/Protease/Amylase17$25,466
FarxigaDapagliflozin Propanediol16$24,659
Buprenorphine77$21,793
Atorvastatin Calcium1,287$21,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$905$383,416307 claims
PfizerEliquis$461$177,139151 claims
GSKTrelegy Ellipta, Breo Ellipta$18$130,403176 claims
AbbVieLinzess, Creon$102$75,60970 claims
Johnson & JohnsonXarelto$123$50,86060 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →